January 27, 2026: The U.S. Food and Drug Administration (FDA) approved the quadruplet therapy daratamumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results